Johnson & Johnson

Rank: 2
2015 Rank1
Employees127,100
Revenue:$25,137,000,000
R&D Spend:$9,046,000,000
Fiscal year ending:01/03/16
Click here to see all 100

RBP Although Johnson and Johnson last year said it was eyeing acquisitions to bolster its "subscale" cardiovascular business, particularly its electrophysiology business, the world's largest medical device business instead sold off a pair of assets: Its Cordis stent-making arm, for $1.94 billion to Cardinal Health; and its Ortho-Clinical Diagnostics business to private equity giant Carlyle Group for $4 billion. JandJ also committed to a $2.5 billion deal to settle a rash of lawsuits filed over its DePuy ASR metal-on-metal hip implant and pulled its laparoscopic power morcellators after the devices were implicated in the unintentional spread of uterine cancers. The company began the year with a transparency pledge for data from its clinical trial programs and launched a robot-assisted surgery pilot program with Google. In 2014 and 2015 to date, Johnson and Johnson Medical Devices companies worked to focus on life-changing and live-saving impacts innovation for patients. We leveraged our scale, depth and breadth while executing a strategy focused on innovation, geographic expansion, executional excellence and market leadership. We acquired Synthes in 2012 to create the most comprehensive orthopaedics company in the industry, and in 2013 consolidated the Ethicon and Ethicon Endo-Surgery businesses to unlock the power of scale and breadth in surgery. We have now integrated our orthopaedics and surgery businesses to enable a more holistic approach to the market and to focus on enhancing our partnerships with hospital customers by leveraging our comprehensive portfolio. Johnson and Johnson continues to believe that the market will reward meaningful innovation that has true patient impact and that advances patient care. We are focused on disciplined portfolio prioritization so that we can reinvest in new technologies that advance patient care. In 2014, we concluded the divestiture of Ortho Clinical Diagnostics and this year, we entered into an agreement to divest our Cordis business to enable us to focus resources on the highest growth opportunities. We are committed to accelerating growth through innovation, and we have already submitted more than half of the 30 major filings we previously announced we planned to file by the end of 2016. Innovation goes beyond product. Our work with Google illustrates how we're aiming to pioneer the operating room of the future with robotic surgical tools that will increase surgical precision minimize trauma for patients, and delivery efficiencies to hospitals. To complement our market-leading products and address hospitals goals, we launched our program and service offering--DePuy Synthes Advantage™--a unique suite of provider-focused solutions focused on complementing the company's extensive portfolio of clinically proven products with solutions that assist in driving optimal clinical and economic outcomes while striving to improve the patient experience. ADDITIONAL INFORMATION: Recent new product launches In surgery, we launched a number of truly differentiated technologies, including the EVARREST® Fibrin Sealant Patch, a novel bio-absorbable hemostat, HARMONIC ACE®+7, an advanced ultrasonic vessel sealing device, ECHELON FLEX™ GST System to control tissue movement during staple firing, and the ECHELON FLEX™ Powered Vascular Stapler with Advanced Placement Tip, our first stapler designed for critical thoracic procedures. In orthopaedics, DePuy Synthes introduced two new technologies for the ATTUNE® Knee System—the ATTUNE Rotating Platform Knee and the Anatomic Patella. We launched CORAIL Revision System, the only tapered wedge hip revision system on the market; it is easier to implant, conserves more bone stock and uses a simpler surgical technique. In 2014, the U.S. FDA approved MONOVISC®, the first non-avian single injection hyaluronic acid (HA) product approved in the U.S. to treat osteoarthritis of the knee to relieve pain and improve mobility. Mitek Sports Medicine worked with Anika Therapeutics to commercially introduce MONOVISC in the United States. This year, DePuy Synthes launched the TFN-Advanced™ (TFNA) Proximal Femoral Nailing System, designed to improve patient outcomes by more closely matching the anatomy of patients. With the incidence of hip fracture on the rise, TFNA is designed to address the most critical needs of an aging population by helping to reduce postoperative complications and costs. TFNA also provides value to surgeons and providers by simplifying procedures, increasing surgical options and reducing hospital costs.

Partners involved in the clinical program for the Ebola vaccine regimen include the Janssen Pharmaceutical Companies of Johnson & Johnson, the London School of Hygiene & Tropical Medicine, the University of Oxford, Inserm, Bavarian Nordic and Europe’s Innovative Medicines Initiative. Johnson & Johnson Consumer Inc. announced that it has entered into a definitive agreement to acquire NeoStrata Company, Inc., a global manufacturer and developer in dermocosmetics.

2015 Top 500 Solar Contractors Key Personnel: Alex Gorsky, Chairman & CEO; Dominic Caruso, CFO; Joaquin Duato, EVP, Chairman, Pharmaceuticals; Peter Fasolo, EVP, Chief HR Officer; Jorge Mesquita, EVP, Chairman, Consumer; Sandra Peterson, EVP, Group Chairman; Gary Pruden, EVP, Chairman, Medical Devices; Michael Sneed, VP, Global Affairs; Dr. Paul Stoffels, EVP, Chief Scientific Officer; Michael Ullmann, EVP, GC; Kathryn Wengel, VP, Supply Chain;

One Johnson and Johnson Plaza
New Brunswick, New Jersey
8933
USA

Additional Resources

"Our work with Google illustrates how we're aiming to pioneer the operating room of the future with robotic surgical tools that will increase surgical precision minimize trauma for patients, and delivery efficiencies to hospitals. To complement our market-leading products and address hospitals goals, we launched our program and service offering--DePuy Synthes Advantage™--a unique suite of provider-focused solutions focused on complementing the company's extensive portfolio of clinically proven products with solutions that assist in driving optimal clinical and economic outcomes while striving to improve the patient experience.

 

ADDITIONAL INFORMATION: Recent new product launches In surgery, we launched a number of truly differentiated technologies, including the EVARREST® Fibrin Sealant Patch, a novel bio-absorbable hemostat, HARMONIC ACE®+7, an advanced ultrasonic vessel sealing device, ECHELON FLEX™ GST System to control tissue movement during staple firing, and the ECHELON FLEX™ Powered Vascular Stapler with Advanced Placement Tip, our first stapler designed for critical thoracic procedures. In orthopaedics, DePuy Synthes introduced two new technologies for the ATTUNE® Knee System—the ATTUNE Rotating Platform Knee and the Anatomic Patella. We launched CORAIL Revision System, the only tapered wedge hip revision system on the market; it is easier to implant, conserves more bone stock and uses a simpler surgical technique. In 2014, the U.S. FDA approved MONOVISC®, the first non-avian single injection hyaluronic acid (HA) product approved in the U.S. to treat osteoarthritis of the knee to relieve pain and improve mobility. Mitek Sports Medicine worked with Anika Therapeutics to commercially introduce MONOVISC in the United States. This year, DePuy Synthes launched the TFN-Advanced™ (TFNA) Proximal Femoral Nailing System, designed to improve patient outcomes by more closely matching the anatomy of patients. With the incidence of hip fracture on the rise, TFNA is designed to address the most critical needs of an aging population by helping to reduce postoperative complications and costs. TFNA also provides value to surgeons and providers by simplifying procedures, increasing surgical options and reducing hospital costs.